Version 1
: Received: 13 October 2024 / Approved: 14 October 2024 / Online: 14 October 2024 (14:53:06 CEST)
How to cite:
Gomes, S. F.; Valois, A.; Estevinho, M. M.; Santiago, M.; Magro, F. Association of Gut Microbiome and Dipeptidyl Peptidase 4 in Immune-Mediated Inflammatory Bowel Disease: A Rapid Literature Review. Preprints2024, 2024101079. https://doi.org/10.20944/preprints202410.1079.v1
Gomes, S. F.; Valois, A.; Estevinho, M. M.; Santiago, M.; Magro, F. Association of Gut Microbiome and Dipeptidyl Peptidase 4 in Immune-Mediated Inflammatory Bowel Disease: A Rapid Literature Review. Preprints 2024, 2024101079. https://doi.org/10.20944/preprints202410.1079.v1
Gomes, S. F.; Valois, A.; Estevinho, M. M.; Santiago, M.; Magro, F. Association of Gut Microbiome and Dipeptidyl Peptidase 4 in Immune-Mediated Inflammatory Bowel Disease: A Rapid Literature Review. Preprints2024, 2024101079. https://doi.org/10.20944/preprints202410.1079.v1
APA Style
Gomes, S. F., Valois, A., Estevinho, M. M., Santiago, M., & Magro, F. (2024). Association of Gut Microbiome and Dipeptidyl Peptidase 4 in Immune-Mediated Inflammatory Bowel Disease: A Rapid Literature Review. Preprints. https://doi.org/10.20944/preprints202410.1079.v1
Chicago/Turabian Style
Gomes, S. F., Mafalda Santiago and Fernando Magro. 2024 "Association of Gut Microbiome and Dipeptidyl Peptidase 4 in Immune-Mediated Inflammatory Bowel Disease: A Rapid Literature Review" Preprints. https://doi.org/10.20944/preprints202410.1079.v1
Abstract
Immune-mediated inflammatory diseases (IMIDs) are characterized by dysregulated immune responses and chronic tissue inflammation. In the setting of inflammatory bowel disease (IBD), dipeptidyl peptidase 4 (DPP4) and gut microorganisms have been proved to interplay, potentially influenced by dietary factors. This rapid review aimed to study the DPP4-gut microbiome link in IBD.
A literature search across five databases and two other sources identified seven relevant studies reporting data on DPP4 and gut microbiome, in patients with IBD-related IMIDs or in vitro or in vivo models: one cross-sectional, one in vitro, and five in vivo studies.
The findings revealed a significant impact of DPP4 and its substrates, i.e. glucagon-like pep-tide-1/2 (GLP-1/2), on the composition of gut microbiome and on the development of dysbiosis. Increased DPP4 activity is associated with decreased GLP-1/2, increased pathogenic bacteria from Actinobacteria, Bacteroidetes, Deferribacteres, Firmicutes, Fusobacteriota, Proteobacteria, and Verrucomicrobia phyla, and decreased -diversity of beneficial gut microbes, including Clostridiaceae, Lachnospiraceae, and Ruminococcaceae families and short-chain fatty ac-id-producing bacteria like Odoribacter and Butryvibrio spp., with exacerbation of intestinal in-flammation.
This overview revealed that understanding the DPP4-gut microbiome association is critical for the development of DPP4-targeted therapeutic strategies to guarantee gut microbiome balance and modulation of immune response in IBD.
Medicine and Pharmacology, Gastroenterology and Hepatology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
